In Vitro Corneal and Conjunctival Wound-Healing Assays as a Tool for Antiglaucoma Prostaglandin Formulation Characterization

Liang H., Baudouin C., Daull P., Garrigue J.-S., Brignole-Baudouin F.

2022
Frontiers in Bioscience

View publication

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

Institut de la Vision, Sorbonne Université, INSERM, CNRS, IHU Foresight, 75012 Paris, France; Quinze-Vingts National Ophthalmology Hospital, IHU Foresight, 75012 Paris, France; University of Versailles Saint Quentin en Yvelines, 78000 Versailles, France; Santen SAS, 91000 Evry, France; Toxicology Department, Faculty of Pharmaceutical and Biological Sciences, Paris Descartes University, 75006 Paris, France

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications